{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10"],"submitter":["Amini L"],"pubmed_abstract":["Viral infections have a major impact on morbidity and mortality of immunosuppressed solid organ transplant (SOT) patients because of missing or failure of adequate pharmacologic antiviral treatment. Adoptive antiviral T-cell therapy (AVTT), regenerating disturbed endogenous T-cell immunity, emerged as an attractive alternative approach to combat severe viral complications in immunocompromised patients. AVTT is successful in patients after hematopoietic stem cell transplantation where T-cell products (TCPs) are manufactured from healthy donors. In contrast, in the SOT setting TCPs are derived from/applied back to immunosuppressed patients. We and others demonstrated feasibility of TCP generation from SOT patients and first clinical proof-of-concept trials revealing promising data. However, "],"journal":["Frontiers in immunology"],"pagination":["1148"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6546853"],"repository":["biostudies-literature"],"pubmed_title":["Comprehensive Characterization of a Next-Generation Antiviral T-Cell Product and Feasibility for Application in Immunosuppressed Transplant Patients."],"pmcid":["PMC6546853"],"pubmed_authors":["Jurisch A","Volk HD","Reinke P","Landwehr-Kenzel S","Amini L","Jurchott K","Schmueck-Henneresse M","Otto NM","Vollmer T","Wendering DJ"],"additional_accession":[]},"is_claimable":false,"name":"Comprehensive Characterization of a Next-Generation Antiviral T-Cell Product and Feasibility for Application in Immunosuppressed Transplant Patients.","description":"Viral infections have a major impact on morbidity and mortality of immunosuppressed solid organ transplant (SOT) patients because of missing or failure of adequate pharmacologic antiviral treatment. Adoptive antiviral T-cell therapy (AVTT), regenerating disturbed endogenous T-cell immunity, emerged as an attractive alternative approach to combat severe viral complications in immunocompromised patients. AVTT is successful in patients after hematopoietic stem cell transplantation where T-cell products (TCPs) are manufactured from healthy donors. In contrast, in the SOT setting TCPs are derived from/applied back to immunosuppressed patients. We and others demonstrated feasibility of TCP generation from SOT patients and first clinical proof-of-concept trials revealing promising data. However, ","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019","modification":"2026-05-07T14:55:05.483Z","creation":"2026-04-29T03:06:43.311Z"},"accession":"S-EPMC6546853","cross_references":{"pubmed":["31191530"],"doi":["10.3389/fimmu.2019.01148"]}}